.mdx

Tube Investments of India in Q4 FY2026: cash-led core, multi-engine bets

Tube Investments of India Limited (TII) closed FY2025-26 with steady profitability in its standalone engineering-led core and a clear push to scale newer platforms through subsidiaries. For Q4 FY2025-26, standalone revenue was 2,279 crore versus 1,957 crore in Q4 FY2024-25. Full-year standalone revenue rose to 8,556 crore from 7,893 crore. Profit before tax, before exceptional items and fair value impacts, increased to 361 crore in Q4 and 1,099 crore for the year.

The most investor-relevant highlight was cash. Management reported standalone free cash flow of 313 crore in Q4 and 826 crore for FY2025-26, stating that full-year free cash flow was 100% of PAT. Pre-tax ROIC was reported at 44% for FY2025-26, unchanged from FY2024-25.

Alongside this, TII continued to expand and professionalize its portfolio. The investor presentation positioned the company as an engineering platform with divisions spanning precision tubes and steel strips, metal formed products, mobility (cycles and fitness), and other businesses like industrial chains. It also showcased multiple subsidiaries in EVs, electrical equipment, medical devices, and contract manufacturing.

Standalone performance: engineering drives, cash follows

TII’s standalone numbers show a business that is growing without losing operating discipline. Over FY2022 to FY2026, revenue from operations rose from 6,359 crore to 8,556 crore. PBT (before exceptional items and fair value gain) increased from 628 crore in FY2022 to 1,099 crore in FY2026.

At a divisional level, the engineering division remained the largest contributor. FY2025-26 engineering revenue was 5,612 crore with PBIT of 689 crore, maintaining a 12% margin. In Q4, engineering revenue grew to 1,495 crore from 1,229 crore.

Metal Formed Products Division (MFP) grew modestly, with FY2025-26 revenue of 1,603 crore versus 1,565 crore in FY2024-25. Q4 PBIT margin slipped to 8% from 10%. Management attributed slower momentum in MFP to delays and economics in railway tender business and muted growth at a key OEM customer.

Mobility (cycles and fitness) delivered FY2025-26 revenue of 783 crore versus 671 crore, while PBIT improved to 19 crore from 5 crore. However, margins stayed low at about 2%, indicating that profitability in this division is still developing.

Other Businesses posted FY2025-26 revenue of 923 crore compared with 987 crore in FY2024-25, but profitability improved sharply with PBIT rising to 70 crore from 48 crore. The presentation highlighted industrial chains as a global brand business with exports and multi-industry end markets.

What management highlighted: demand, costs, and the lag effect

In the earnings call, analysts asked whether revenue growth reflected volumes or price. Management stated that Q4 sales growth was broadly in line with volume growth because there were no major price movements.

On the demand outlook, management said volumes were still on the stronger side and described the growth environment as bullish at that point. At the same time, it flagged two margin pressures. First, commodity price increases were recoverable via customer contracts, but typically with a one to two quarter lag. Second, fuel inflation was described as an immediate challenge, with discussions ongoing with customers and internal cost actions planned.

On railways, management said product development work was completed, but customer approvals with the Government of India for Vande Bharat coach programs were still in progress, with progress expected over the next two to three quarters.

Subsidiaries and new platforms: EV deployment, medical devices, CDMO

TII’s consolidated narrative includes multiple subsidiaries, but two platforms drew the most questions in the call: TI Clean Mobility (EVs) and TI Medical.

TI Clean Mobility: order book versus deployment constraints

TII disclosed cumulative investments into TI Clean Mobility of 250 crore as equity and 750 crore as compulsorily convertible preference shares. During FY2025-26, TI Clean Mobility invested 245 crore in TIVOLT to raise its stake to 100% and invested 280 crore in IPLTech Electric to increase its stake to 95.58%.

Management described an upswing in demand for electric vehicles, especially in heavy trucks and small commercial vehicles, and said it was sitting on a strong order book for heavy trucks. The constraint was not demand, but deployment.

It identified two deployment bottlenecks: financing for fleet-scale deployments (often 50 to 100 trucks, translating into 100 crore-plus capital needs) and charging infrastructure setup for routes. It expressed confidence in untangling these issues and indicated deployments could pick up in Q1 and Q2.

Management also provided Q4 EV volumes: 87 heavy trucks, 241 small commercial vehicles, 1,176 three-wheelers, and no tractor billing.

Three-wheelers faced a supply-side issue. Management said a body-in-white supplier constraint forced production to run at around 50% of potential in Q4, affecting billing and retail. It said the issue was resolved by taking over the supplier’s facility close to its existing unit, and that April and May showed ramp-up progress, with further stabilization expected by the end of Q1.

On technology choices for long haul applications, management said battery swapping has speed advantages but requires heavy setup costs, while higher battery capacities and fast charging appear to be emerging as the preferred solution in many use cases. It stated the company is not abandoning swap technology, citing applications like ports.

TI Medical: export headwinds, growth guidance, and IV cannula entry

The investor presentation stated that TII has invested 265 crore in TI Medical Private Limited as of 31 March 2026. In the call, management said regulatory aspects for exports were completed, but Middle East demand became a headwind, which muted near-term scale-up. It indicated progress in Europe and Southeast Asia.

Importantly, management guided that TI Medical could grow 15% to 20% year-on-year. It also disclosed an asset purchase of a Medicura facility in Ambala for IV cannula, noting the facility was not operational and required plant approvals and hiring. Management expected these steps to complete over Q1 and Q2, enabling start of commercial production thereafter.

3xper Innoventure: CDMO plant commissioning

On 3xper Innoventure, management stated the Naidupet facility is under final commissioning and commercial production is expected to begin next quarter. The investor deck describes 3xper as an integrated CRO/CDMO platform with discovery, development, and manufacturing services.

Capital allocation: capex and ongoing investments

For FY2026-27, management indicated standalone core business capex of around 300 crore to 350 crore. It also said additional funding would be required for subsidiaries depending on operational scaling, specifically naming TI Clean Mobility and TI Medical.

The call also discussed EV cost reduction and localization as ongoing priorities across platforms. Management noted that cost reduction efforts were facing headwinds from geopolitical situations, but remained a top priority.

Closing takeaways

TII’s FY2025-26 disclosure set up a clear picture. The standalone core delivered growth with strong cash generation and stable ROIC, while the company continued to build multiple long-term engines through subsidiaries.

The near-term investor questions are concentrated in execution. EVs need financing and infrastructure solutions to convert order books into deliveries. Medical devices need export traction to match the platform ambition. And a few segments like MFP and Shanthi Gears need demand recovery and margin stabilization.

Still, the FY2025-26 combination of high cash conversion, stable returns, and candid operating commentary suggests a company trying to fund optionality without compromising the core.